Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ICPT

Intercept Pharmaceuticals Inc

ICPT

19.00USD Delayed
Watchlist

Market Summary

USD19.00
Delayed

ICPT Alerts

  • 17 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

ICPT Stock Price

View Fullscreen

ICPT RSI Chart

ICPT Valuation

Market Cap

794.4M

Price/Earnings (Trailing)

-12.89

Price/Sales (Trailing)

2.5

Price/Free Cashflow

-12.7

ICPT Price/Sales (Trailing)

ICPT Profitability

Operating Margin

99.80%

Return on Equity

-85.76%

Return on Assets

-15.67%

Free Cashflow Yield

-7.88%

ICPT Fundamentals

ICPT Revenue

Revenue (TTM)

317.7M

Revenue Y/Y

14.44%

Revenue Q/Q

6.06%

ICPT Earnings

Earnings (TTM)

-61.6M

Earnings Y/Y

-101.04%

Earnings Q/Q

52.41%

Price Action

Last 7 days

0.1%

Last 30 days

1.4%

Last 90 days

81.3%

Trailing 12 Months

19.1%

How does ICPT drawdown profile look like?

ICPT Financial Health

Current Ratio

4.22

ICPT Investor Care

Shares Dilution (1Y)

0.95%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023294.5M306.5M317.7M0
2022262.6M266.2M277.1M285.7M
2021297.3M288.3M275.4M260.8M
2020272.4M283.4M300.9M312.7M
2019196.1M218.8M233.8M252.0M
2018145.9M158.6M164.2M179.8M
201745.6M70.9M107.1M131.0M
20161.8M6.9M11.6M25.0M
20152.8M2.8M2.8M2.8M
20141.6M1.7M1.7M1.7M
20132.1M1.7M1.6M1.6M
20122.6M2.9M2.8M2.4M
20110001.8M

Latest Insider Trading transactions for ICPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 08, 2023
miller-rich nancy
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
benatti luca
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
santini gino
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
ford david a
back to issuer
-406,600
19.00
-21,400
chief human resources officer
Nov 08, 2023
miller-rich nancy
sold
-423,776
19.00
-22,304
-
Nov 08, 2023
akkaraju srinivas
sold
-719,853
19.00
-37,887
-
Nov 08, 2023
saik andrew
back to issuer
-859,636
19.00
-45,244
evp & chief financial officer
Nov 08, 2023
venezia rocco
sold
-204,858
19.00
-10,782
chief accounting officer
Nov 08, 2023
akkaraju srinivas
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
venezia rocco
back to issuer
-278,711
19.00
-14,669
chief accounting officer

1–10 of 50

Which funds bought or sold ICPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-87.65
-10,186,200
2,658,900
-%
Nov 29, 2023
Carmignac Gestion
new
-
1,580,920
1,580,920
0.03%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-34.42
24,718
273,557
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-170,058
-
-%
Nov 21, 2023
Alpine Global Management, LLC
new
-
1,656,000
1,656,000
0.21%
Nov 21, 2023
COMERICA BANK
new
-
358
358
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-9,531,520
-
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
44.03
162,754
277,822
-%
Nov 15, 2023
Tudor Investment Corp Et Al
new
-
463,500
463,500
-%
Nov 15, 2023
PIN OAK INVESTMENT ADVISORS INC
unchanged
-
1,000
3,000
-%

1–10 of 35

Latest Funds Activity

Are funds buying ICPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ICPT
No. of Funds

Schedule 13G FIlings of Intercept Pharmaceuticals Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Oct 10, 2023
vanguard group inc
4.95%
2,071,222
SC 13G/A
Jul 10, 2023
vanguard group inc
11.26%
4,693,807
SC 13G/A
Jul 07, 2023
blackrock inc.
10.5%
4,396,970
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
0.4%
166,300
SC 13G/A
Feb 09, 2023
vanguard group inc
8.78%
3,637,935
SC 13G/A
Feb 02, 2023
state street corp
7.67%
3,175,925
SC 13G/A
Jan 31, 2023
blackrock inc.
7.4%
3,084,833
SC 13G/A
Jan 13, 2023
millennium management llc
2.4%
976,706
SC 13G/A
Sep 02, 2022
genextra s.p.a.
13.4%
4e+06
SC 13G/A
Aug 18, 2022
millennium management llc
5.1%
1,524,316
SC 13G

Recent SEC filings of Intercept Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Nov 20, 2023
15-12G
15-12G
Nov 14, 2023
EFFECT
EFFECT
Nov 14, 2023
EFFECT
EFFECT
Nov 14, 2023
EFFECT
EFFECT
Nov 13, 2023
4
Insider Trading
Nov 13, 2023
4
Insider Trading
Nov 13, 2023
4
Insider Trading
Nov 13, 2023
4
Insider Trading
Nov 13, 2023
4
Insider Trading
Nov 13, 2023
4
Insider Trading

ICPT Fair Value

Loading...

Peers (Alternatives to Intercept Pharmaceuticals Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
6.13% 411799.31%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
12.59% -56.51%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
0.38% -28.56%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
8.71% -10.95%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
1.18% -34.97%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
33.62% 24.68%
-12.26
27.23
141.38% 4.43%
5.7B
-
10.65% 240.88%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-9.53% 43.40%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
14.00% -9.85%
-16.45
14.86
- -26.24%
2.6B
240.7M
-11.63% -24.14%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
12.92% -15.71%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-18.09% -67.84%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.35%
-0.61
15.6
-44.11% 50.48%
37.6M
-
385.71% 119.35%
-0.58
-
- -29.23%
23.7M
-
40.31% 4064.72%
-0.5
-
- -13.74%

Intercept Pharmaceuticals Inc News

Latest updates
Defense World01 Dec 202309:20 am8 days ago
Morningstar14 Nov 202308:00 am25 days ago
Intercept Pharmaceuticals, Inc.08 Nov 202308:00 am31 days ago
Beaumont Enterprise07 Nov 202308:00 am32 days ago
Yahoo Finance31 Oct 202307:00 am39 days ago
Business Wire26 Oct 202307:00 am44 days ago
PR Newswire24 Oct 202307:00 am46 days ago
PR Newswire23 Oct 202307:00 am47 days ago
InvestorPlace19 Oct 202307:00 am51 days ago
Yahoo Finance11 Oct 202307:00 am59 days ago
BioSpace11 Oct 202307:00 am59 days ago
PR Newswire09 Oct 202307:00 am2 months ago
Stockhouse Publishing04 Oct 202307:00 am2 months ago
Nasdaq02 Oct 202307:00 am2 months ago
Digital Journal01 Oct 202307:00 am2 months ago

Financials for Intercept Pharmaceuticals Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue6.1%89.0084.0068.0077.0078.0072.0059.0069.0067.0068.0057.0083.0080.0077.0073.0072.0062.0066.0052.0053.0047.00
Cost Of Revenue6.5%0.000.000.000.000.000.000.000.000.000.001.00-2.202.002.001.002.000.001.001.001.001.00
Costs and Expenses2.8%93.0091.0010095.0088.0085.0086.0090.0086.0082.0011144.00135129156161137130136135105
Operating Expenses-------------------136135105
  S&GA Expenses-14.8%45.0053.0058.0055.0043.0040.0038.0040.0041.0044.0059.00-2.0371.0093.0099.0094.0077.0070.0077.0071.0057.00
  R&D Expenses11.3%42.0037.0042.0040.0044.0045.0048.0050.0045.0038.0051.0049.0049.0034.0057.0065.0060.0060.0058.0063.0048.00
Interest Expenses-35.9%2.003.003.003.005.007.007.0015.0014.0013.0012.0012.0012.0012.0012.0012.0012.0010.008.008.008.00
Net Income52.4%-2.79-5.86-32.13-20.82267-7.53-17.28-36.28-3.63-11.09-40.42-52.15-66.47-63.28-92.98-98.16-84.83-71.42-90.27-88.00-64.45
Net Income Margin-128.5%-0.19*0.68*0.70*0.78*0.67*-0.15*-0.18*-0.25*-0.30*-0.50*-0.69*-0.88*-1.07*-1.20*-1.28*-1.37*-1.43*-1.44*-1.62*-1.72*-2.02*
Free Cashflow-17.00--51.30-4.51-16.9214.00-20.134.004.005.00-55.03-17.88-41.81-15.07-99.16-60.58-46.77-46.24-84.16-52.93-51.58
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-18.9%393485504554559499503527523523520580591637662755802853438509557
  Current Assets-18.5%383471490540545487477508496493488546561607628721769819403482529
    Cash Equivalents-24.6%10313661.0051.0011358.0048.0085.0068.0014693.0058.0045.0051.0041.0070.0063.0094.0055.0043.0059.00
  Inventory-------------------7.007.007.00
  Net PPE-9.3%1.001.001.001.001.001.003.003.004.005.005.006.005.004.005.005.006.007.007.0010.0011.00
Liabilities-23.0%321417437461452868875711679726720747722716697703671678493490461
  Current Liabilities-51.4%91.0018720723022215115116814414514617916316415016214012510811488.00
    LT Debt, Non Current0.1%224224223223223714717540530576568561553546539532525545375371367
Shareholder's Equity6.4%72.0068.0067.0093.00108-369--183-------52.00131175-19.0096.00
  Retained Earnings-0.1%-2,177-2,174-2,169-2,136-2,116-2,383-2,375-2,489-2,453-2,449-2,438-2,398-2,346-2,279-2,216-2,123-2,025-1,940-1,869-1,778-1,690
  Additional Paid-In Capital0.3%2,2572,2502,2442,2382,2322,0162,0082,3092,3002,2492,2412,2342,2182,2022,1862,1762,1572,1161,8151,8001,788
Shares Outstanding0.1%42.0042.0042.0042.0041.0030.0030.0030.0032.0033.0033.0033.0033.0033.0033.0033.0031.0031.0030.0028.0030.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations171.6%16,686-23,302-51,597-4,806-16,58814,738-20,1245,1753,5624,847-54,650-17,813-40,478-14,842-98,731-60,484-46,756-45,948-83,425-52,812-51,581
  Share Based Compensation6.2%6,6536,2625,8645,2315,7885,4895,3817,1517,1885,2748,4194,80515,82516,08312,47313,17313,13014,78214,89711,49911,994
Cashflow From Investing-38.3%59,77496,94659,323-54,935331,582-578-14,22015,328-84,25748,31591,34029,84435,09226,06471,81765,88816,475-365,81894,46736,92931,542
Cashflow From Financing-255711.6%-109,999-43.00-254-5,672-257,402-3,924-318-9653,390-224-1,083-156-226442-7535,880892450,5951524401,262

ICPT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations    
Revenue$ 88,789$ 77,588$ 240,465$ 208,491
Revenue, Product and Service [Extensible Enumeration]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Operating expenses:    
Cost of sales$ 197$ 424$ 604$ 956
Selling, general and administrative45,43843,274156,441121,013
Research and development41,51344,034120,530136,753
Restructuring6,260 6,260 
Total operating expenses93,40887,732283,835258,722
Operating loss(4,619)(10,144)(43,370)(50,231)
Other income (expense):    
Interest expense(1,802)(5,237)(7,423)(18,579)
Loss on extinguishment of debt (91,759) (91,739)
Other income, net3,6613,05310,3262,691
Total other income (expense), net1,859(93,943)2,903(107,627)
Loss from continuing operations(2,760)(104,087)(40,467)(157,858)
(Loss) income from discontinued operations, net of income taxes(30)371,540(320)400,499
Net (loss) income$ (2,790)$ 267,453$ (40,787)$ 242,641
Net income (loss) per common and potential common share (basic and diluted):    
Net loss from continuing operations, Basic (in dollars per share)$ (0.07)$ (3.04)$ (0.97)$ (5.05)
Net loss from continuing operations, Diluted (in dollars per share)(0.07)(3.04)(0.97)(5.05)
Net (loss) income from discontinued operations, Basic (in dollars per share)0.0010.83(0.01)12.81
Net (loss) income from discontinued operations, Diluted (in dollars per share)0.0010.83(0.01)12.81
Net (loss) income, Basic (in dollars per share)(0.07)7.80(0.98)7.76
Net (loss) income, Diluted (in dollars per share)$ (0.07)$ 7.80$ (0.98)$ 7.76
Weighted average common and potential common shares outstanding:    
Basic (in shares)41,79234,29341,73131,262
Diluted (in shares)41,79234,29341,73131,262

ICPT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 102,736$ 50,517
Restricted cash9205,343
Investment debt securities, available-for-sale219,978435,049
Accounts receivable, net of allowance for credit losses of $65 and $54, respectively32,47926,862
Prepaid expenses and other current assets27,33222,356
Total current assets383,445540,127
Fixed assets, net822987
Inventory2,6496,462
Security deposits1,2751,013
Other assets4,9715,122
Total assets393,162553,711
Current liabilities:  
Accounts payable, accrued expenses and other liabilities89,494116,977
Short-term interest payable1,3513,531
Current portion of long-term debt 109,569
Total current liabilities90,845230,077
Long-term liabilities:  
Long-term debt223,856223,104
Long-term other liabilities6,6167,453
Total liabilities321,317460,634
Commitments and contingencies (Note 15)
Stockholders' equity:  
Common stock par value $0.001 per share; 90,000,000 shares authorized; 41,811,686 and 41,523,337 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively4242
Additional paid-in capital2,256,6812,238,179
Accumulated other comprehensive loss, net(7,203)(8,256)
Accumulated deficit(2,177,675)(2,136,888)
Total stockholders' equity71,84593,077
Total liabilities and stockholders' equity$ 393,162$ 553,711
ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
 CEO
 WEBSITEwww.interceptpharma.com
 EMPLOYEES341

Intercept Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Intercept Pharmaceuticals Inc? What does ICPT stand for in stocks?

ICPT is the stock ticker symbol of Intercept Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intercept Pharmaceuticals Inc (ICPT)?

As of Tue Nov 14 2023, market cap of Intercept Pharmaceuticals Inc is 794.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart. The fair value of Intercept Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intercept Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intercept Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ICPT is over valued or under valued. Whether Intercept Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Intercept Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICPT.

What is Intercept Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 14 2023, ICPT's PE ratio (Price to Earnings) is -12.89 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intercept Pharmaceuticals Inc's stock?

In the past 10 years, Intercept Pharmaceuticals Inc has provided -0.096 (multiply by 100 for percentage) rate of return.